Kala Pharmaceuticals (NASDAQ:KALA) Third Quarter 2022 Results
Key Financial Results
Net income: US$29.1m (up from US$28.1m loss in 3Q 2021).
EPS: US$19.40 (up from US$21.62 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kala Pharmaceuticals EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 99%. Earnings per share (EPS) exceeded analyst estimates by 79%.
Looking ahead, revenue is expected to decline by 45% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 3.9%.
The company's shares are up 12% from a week ago.
You should learn about the 6 warning signs we've spotted with Kala Pharmaceuticals (including 3 which can't be ignored).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here